SEC Form 4 · accession 0001171843-15-006553
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank A Holler
Director
Period of report
Nov 24, 2015
Accepted (ET)
Nov 25, 2015 · 3:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Nov 24, 2015 | M | 2,057 | $5.22 | A | 176,864 | D | |
| Common SharesF2 | Nov 24, 2015 | F | 995 | $9.39 | D | 175,869 | D | |
| Common Shares | holding | — | — | — | 1,184 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $5.22 | Nov 24, 2015 | M | 2,057 | D | — | Dec 31, 2015 | Common Shares | 2,057 | 0 | D |
Explanation of responses
- F1The exercise price was converted to U.S. dollars from $6.07 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares in U.S. dollars on November 23, 2015, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on January 1, 2009.